Article

The Economics of the Biopharmaceutical Industry

Patricia M. Danzon

in The Oxford Handbook of Health Economics

Published in print April 2011 | ISBN: 9780199238828
Published online September 2012 | | DOI: http://dx.doi.org/10.1093/oxfordhb/9780199238828.013.0022

Series: Oxford Handbooks in Economics

 The Economics of the Biopharmaceutical Industry

More Like This

Show all results sharing these subjects:

  • Economics
  • Health, Education, and Welfare
  • Public Economics

GO

Show Summary Details

Preview

This article summarizes the literature, and considers the issue of paying for research and development. It reviews research and development costs, regulation, productivity and incentives for innovation. It discusses market demand and pricing, effects of insurance, reimbursement regulation, alternatives to patents, and generics. Further, it reviews trends in promotion, regulation of promotion and its effects. It discusses global issues, including differential pricing and R&D for neglected diseases. The focus is on the US, as the home of the largest number of multinational pharmaceutical and smaller biotech companies. This article notes the important differences in regulatory and reimbursement systems in other countries. Finally it suggests that although there is large and growing literature on the pharmaceutical industry that has produced valuable information, important issues remain for future research.

Keywords: research and development; generics; pharmaceutical; reimbursement; productivity

Article.  16293 words. 

Subjects: Economics ; Health, Education, and Welfare ; Public Economics

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.